BioNeutral Group Develops New Antimicrobial Technology Platform

NEWARK, N.J., Oct. 14 /PRNewswire/ -- BioNeutral Group, Inc. (OTC Bulletin Board: BONU), a specialty chemical technology-based life science company announced today that it has developed a new antimicrobial technology platform with excellent kill times and long residual efficacies specifically applicable to industrial manufacturing environments. These new products expand BioNeutral's product offering and expands new business opportunities in the industrial manufacturing sector, especially where hydrocarbons and hydrocarbon emulsions are used in metal forming, grinding, treatment industries and the specialty petrochemical industry.

The chart below is an indicative representation of the summary of the new product efficacy using typical Gram positive and Gram negative bacteria. The data represents demonstration of the rapid kill of harmful microorganisms and also residual efficacy against these microorganisms after five days of initial antimicrobial treatment. Additional testing for microorganisms, such as Myco bacteria, is in progress.

Dr. Andy Kielbania, Chief Scientist of BioNeutral Group, Inc. said, "I believe this new technology platform and resulting products nicely complement our existing products. Our original Ygiene™ antimicrobials are water based and as such are not readily compatible with hydrocarbon systems. In contrast, our new antimicrobials are miscible with oil type materials. As a result, we are especially focusing these new products for hydrocarbon based applications where I believe these new products will deliver an attractive cost performance profile for a multitude of industrial applications which we could not previously address. The antimicrobial preservation of specialty oils and fluids is a particularly attractive business area which we are focusing upon with these new products. In addition these new products should have utility in a wide variety of plastics such as polyethylene, polypropylene, polyester and polyvinyl chloride where protection against microorganisms is required."

Dr. Vasu Kulkarni, Director of Marketing and Technical Service at British Petroleum and an Advisor to BioNeutral, added, " If the bacterial growth in industrial products, such as lubricating oils, metal working fluids, hydraulic oils, greases and cooling water, can be controlled and where productivity and degradation of the virgin products can be controlled, I believe that the new products could find applications in the industries related to metal cutting, grinding and many heat removal systems. In addition, if these products prove to have low toxicity to humans and the environment compared to current products in use, it could be a compelling product for trails in actual industrial applications. This product could have potential to reduce production down time and eliminate industrial hygiene issues in an industrial work environment."

About BioNeutral Group, Inc.

Headquartered at the New Jersey Institute of Technology/EDC in Newark, BioNeutral Group, Inc., is a technology-based life science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, Ygiene and Ogiene, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace.  BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene™ brand have been submitted to the EPA for approval for sale in the United States and has already been approved for sale in Germany and is permitted to be sold in the UK, France and Sweden. For more information, see www.bioneutralgroup.com

Forward-Looking Statements

This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene(TM) and are not yet available for sale in the United States.

SOURCE BioNeutral Group, Inc.